ストックスクリーナーアプリを入手
3.78
1.31%
-0.05
前日終値:
$3.83
開ける：
$3.86
24時間の取引高:
28,532
Relative Volume:
0.06
時価総額：
$40.39M
収益：
-
当期純損益:
-
株価収益率:
-5.3299
EPS:
-0.7092
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+5.89%
1か月 パフォーマンス:
-14.48%
6か月 パフォーマンス:
+200.00%
1年 パフォーマンス:
+102.14%
1日の値動き範囲:
$3.70
$3.97
1週間の範囲:
$3.52
$3.97
52週間の値動き範囲:
$1.001
$5.87
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
ATHE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
3.78 | 40.39M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-03 | ダウングレード | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 開始されました | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr (ATHE) 最新ニュース
Alterity Therapeutics announces compliance notice - Investing.com
Alterity Therapeutics Issues Over 1 Billion New Shares - TipRanks
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics raises A$40M in placement - TipRanks
Alterity secures funding to advance MSA drug development - Investing.com India
JPMorgan Ceases Substantial Holding in Alterity Therapeutics - TipRanks
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks
JPMorgan Becomes Substantial Holder in Alterity Therapeutics - TipRanks
Alterity Therapeutics reports compliance with Takeovers Panel By Investing.com - Investing.com South Africa
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics Discloses Equity Derivative Positions of Point72 - TipRanks
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics Completes Significant Share Issuance - TipRanks
Alterity Therapeutics Quotes Over 164 Million Securities on ASX - TipRanks
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Announces Major Securities Placement - TipRanks
Alterity Therapeutics Secures Funding to Advance Neurodegenerative Drug Development - TipRanks
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Predictive Oncology Inc (NASDAQ: POAI) Stock Is A Good Option To Consider - Stocks Register
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks
Alterity Therapeutics Expands ASX Quoted Securities - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks
Opthea reports positive Phase 1b DME trial results - Investing.com
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
Alterity Therapeutics reports annual general meeting results By Investing.com - Investing.com South Africa
Alterity Therapeutics reports annual general meeting results - Investing.com India
Alterity Therapeutics announces change in company secretary - Investing.com
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - Yahoo Finance
Opthea adds Kathy Connell to Board of Directors - Investing.com
Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com
Alterity Therapeutics announces change in share registry - Investing.com
Alterity Therapeutics announces change in share registry By Investing.com - Investing.com UK
Opthea Ltd stock soars to 52-week high, hits $4.47 - Investing.com India
Alterity Therapeutics names new CFO - Investing.com India
Alterity Therapeutics discloses annual report for 2024 - Investing.com
ATHEAlterity Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY: ASX - Financial Content
Alterity Therapeutics Ltd Adr (ATHE) 財務データ
Alterity Therapeutics Ltd Adr (ATHE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.39%
0.55%
大文字化:
|
ボリューム (24 時間):